Ethical Dilemma with Stakeholders
You're the CEO of a pharmaceutical company. Your best-selling drug ($2B annual revenue, used by 4 million patients for chronic pain) has…
I would treat this as an urgent patient-safety and governance event, not as an earnings-management problem. A suspected fatal or life-threatening adverse effect affecting potentially hundreds of patients is sufficient to trigger immediate escalation, investigation, and regulator contact.Read the full answer
You have a patient safety issue, not a PR issue. The 6 month regulatory reporting timeline is the formal process, not the ethical or legal obligation to act now. Waiting for more data while patients continue to be exposed is criminal negligence exposure, not risk mitigation.Read the full answer